Manila Times Business
European Commission grants marketing authorization to Pharming’s Joenja® (leniolisib) - the first approved treatment for APDS in the European Union
Joenja® (leniolisib) is first approved treatment in the European Union for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients aged 12 years and olderFirst European launch expected in Germany in Q3 2026Approval adds to Joenja® approvals in the United States, United Kingdom, Japan, Australia and Israel, supporting Pharming’s global expansion strategyLeiden, the Netherlands, May 22, 2026: Pharming Group ("Pharming” or
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
1h ago
Ghana's 'anti-LGBTQ' law triggers both praise and outrage
2h ago
WHO chief visits epicentre of Ebola outbreak in DR Congo
2h ago
Vapofil Reviews [URGENT REPORT 2026] The Shocking VapoFil Male Enhancement Supplement Trend Everyone Is Talking About
2h ago